<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4131280</article-id><article-id pub-id-type="doi">10.3389/fendo.2014.00133</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Gene Expression Profiling in Mouse Embryonic Stem Cells Reveals Glycogen Synthase Kinase-3-Dependent Targets of Phosphatidylinositol 3-Kinase and Wnt/&#x003b2;-Catenin Signaling Pathways</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bartman</surname><given-names>Colleen M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/176528"/></contrib><contrib contrib-type="author"><name><surname>Egelston</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kattula</surname><given-names>Sravya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zeidner</surname><given-names>Leigh C.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Ippolito</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Doble</surname><given-names>Bradley W.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/140978"/></contrib><contrib contrib-type="author"><name><surname>Phiel</surname><given-names>Christopher J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/166419"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Integrative Biology, University of Colorado Denver</institution>, <addr-line>Denver, CO</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Center for Human and Molecular Genetics, Research Institute at Nationwide Children&#x02019;s Hospital</institution>, <addr-line>Columbus, OH</addr-line>, <country>USA</country></aff><aff id="aff3"><sup>3</sup><institution>Stem Cell and Cancer Research Institute, Department of Biochemistry and Biomedical Sciences, McMaster University</institution>, <addr-line>Hamilton, ON</addr-line>, <country>Canada</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Marc Lee Goalstone, University of Colorado Denver, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Kazunori Sango, Tokyo Metropolitan Institute of Medical Science, Japan; Zhong Q Wang, Pennington Biomedical Research Center, USA</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Christopher J. Phiel, Department of Integrative Biology, University of Colorado Denver, Campus Box 171, P.O. Box 173364, Denver, CO 80217-3364, USA e-mail: <email>christopher.phiel@ucdenver.edu</email></corresp><fn fn-type="present-address" id="fn001"><p><sup>&#x02020;</sup>Present address: Anthony D&#x02019;Ippolito, Duke Institute for Genome Sciences &#x00026; Policy, Duke University, Durham, NC, USA</p></fn><fn fn-type="other" id="fn002"><p>This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology.</p></fn></author-notes><pub-date pub-type="epreprint"><day>27</day><month>6</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>13</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>5</volume><elocation-id>133</elocation-id><history><date date-type="received"><day>09</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Bartman, Egelston, Kattula, Zeidner, D&#x02019;Ippolito, Doble and Phiel.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Glycogen synthase kinase-3 (Gsk-3) activity is an important regulator of numerous signal transduction pathways. Gsk-3 activity is the sum of two largely redundant proteins, Gsk-3&#x003b1; and Gsk-3&#x003b2;, and in general, Gsk-3 is a negative regulator of cellular signaling. Genetic deletion of both <italic>Gsk-3</italic>&#x003b1; and <italic>Gsk-3</italic>&#x003b2; in mouse embryonic stem cells (ESCs) has previously been shown to lead to the constitutive activation of the Wnt/&#x003b2;-catenin signaling pathway. However, in addition to Wnt signaling, all Gsk-3-regulated pathways, such as insulin signaling, are also affected simultaneously in <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>ESCs. In an effort to better understand how specific signaling pathways contribute to the global pattern of gene expression in <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>ESCs, we compared the gene expression profiles in <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup> ESCs to mouse ESCs in which either Wnt/&#x003b2;-catenin signaling or phosphatidylinositol 3-kinase (PI3K)-dependent insulin signaling are constitutively active. Our results show that Wnt signaling has a greater effect on up-regulated genes in the <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>ESCs, whereas PI3K-dependent insulin signaling is more responsible for the down-regulation of genes in the same cells. These data show the importance of Gsk-3 activity on gene expression in mouse ESCs, and that these effects are due to the combined effects of multiple signaling pathways.</p></abstract><kwd-group><kwd>embryonic stem cells</kwd><kwd>glycogen synthase kinase-3</kwd><kwd>Wnt</kwd><kwd>phosphatidylinositol 3-kinase</kwd><kwd>microarray</kwd><kwd>quantitative PCR</kwd><kwd>signal transduction</kwd><kwd>gene expression</kwd></kwd-group><counts><fig-count count="5"/><table-count count="4"/><equation-count count="0"/><ref-count count="63"/><page-count count="12"/><word-count count="8608"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Glycogen synthase kinase-3 (Gsk-3) is an intracellular serine/threonine kinase activity that was originally identified as the rate-limiting step in the glycogen synthesis pathway (<xref rid="B1" ref-type="bibr">1</xref>). When the genes encoding Gsk-3 were cloned, Gsk-3 activity was revealed as the combined action of two distinct genes, <italic>Gsk-3</italic>&#x003b1; and <italic>Gsk-3</italic>&#x003b2; (<xref rid="B2" ref-type="bibr">2</xref>). Gsk-3 isoforms show a high degree of similarity at the amino acid level, including 98% similarity within the catalytic domain. Despite divergence at the amino- and carboxyl-termini of each isoform, it appears that the unstructured carboxyl-termini are essential for Gsk-3 activity (<xref rid="B3" ref-type="bibr">3</xref>). Rare among kinases, Gsk-3 is active at a basal state, while pathway activation from upstream signaling cascades results in the inhibition of Gsk-3 activity (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>).</p><p>There are two primary mechanisms responsible for Gsk-3 inhibition &#x02013; one that regulates the phosphorylation of Gsk-3&#x003b1; and Gsk-3&#x003b2; on serines 21 and 9, respectively, and another that is independent of this phosphorylation event. Several signaling pathways, including protein kinase A (PKA), Hedgehog, transforming growth factor-&#x003b2; (TGF-&#x003b2;), nuclear factor of activated T-cells (NF-AT), and phosphatidylinositol 3-kinase (PI3K)-dependent insulin signaling, all affect Gsk-3 activity via phosphorylation of the amino-terminal serines (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>). Insulin binding to its receptor triggers the activation of PI3K, which phosphorylates and activates Akt, which in turn phosphorylates and inhibits Gsk-3 activity (<xref rid="B7" ref-type="bibr">7</xref>). We have previously shown that stable expression of a constitutively active form of the p110&#x003b1; catalytic subunit of PI3K (termed p110*) (<xref rid="B8" ref-type="bibr">8</xref>) in WT mouse ESCs can effectively lead to the phosphorylation of Gsk-3 (<xref rid="B9" ref-type="bibr">9</xref>), and expression of p110* has been shown to activate insulin signaling in mouse ESCs (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Gsk-3 activity also plays a central role in Wnt signaling as it is part of a cytosolic protein complex termed the &#x003b2;-catenin destruction complex (<xref rid="B11" ref-type="bibr">11</xref>). The role of Gsk-3 is to directly phosphorylate &#x003b2;-catenin (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>), which targets &#x003b2;-catenin for ubiquitin-mediated degradation (<xref rid="B14" ref-type="bibr">14</xref>), keeping the Wnt pathway inactive. Activation of the Wnt signaling pathway inhibits Gsk-3 activity, but this effect is not mediated through amino-terminal serine phosphorylation. Instead, upon Wnt ligand binding to a Frizzled/Lrp receptor complex, the destruction complex is neutralized via the translocation of Gsk-3 to the cell membrane, where it phosphorylates Lrp (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Gsk-3 is then subsequently endocytosed into multivesicular bodies, further insulating it from &#x003b2;-catenin (<xref rid="B17" ref-type="bibr">17</xref>). Once &#x003b2;-catenin protein levels accumulate to high levels in the cytoplasm, it is subsequently translocated to the nucleus where it can directly complex with lymphocyte enhancer factor (Lef)/T-cell factor (Tcf) proteins to activate Wnt target genes (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Gsk-3&#x003b1; and Gsk-3&#x003b2; are redundant with respect to their roles in regulating Wnt signaling; the genetic deletion of either <italic>Gsk-3</italic>&#x003b1; or <italic>Gsk-3</italic>&#x003b2; alone is insufficient to activate Wnt signaling (<xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>). Only upon the deletion of three of the four total alleles for Gsk-3&#x003b1; and Gsk-3&#x003b2; is Wnt pathway activation achieved (<xref rid="B23" ref-type="bibr">23</xref>). Double knockout of both <italic>Gsk-3</italic>&#x003b1; and <italic>Gsk-3</italic>&#x003b2; in mouse embryonic stem cells (ESCs) (<xref rid="B23" ref-type="bibr">23</xref>) or mouse neural progenitors (<xref rid="B26" ref-type="bibr">26</xref>) results in the constitutive activation of the Wnt pathway. Importantly, while Gsk-3 regulates both insulin and Wnt signaling, these pathways do not activate one another; Wnt signaling does not activate insulin signaling and insulin signaling does not activate Wnt signaling (<xref rid="B27" ref-type="bibr">27</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>).</p><p>Lithium is a direct inhibitor of Gsk-3 activity (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>) and is used therapeutically for the treatment of bipolar disorder (<xref rid="B32" ref-type="bibr">32</xref>). The inhibition of Gsk-3 activity has also been shown to be a potential means to reduce the pathology associated with Alzheimer&#x02019;s disease (<xref rid="B33" ref-type="bibr">33</xref>&#x02013;<xref rid="B38" ref-type="bibr">38</xref>). Because the dysregulation of Gsk-3 activity is believed to be an important contributor to many diseases, including Alzheimer&#x02019;s disease, cancer, mental illness, and diabetes, the acquisition of more fundamental knowledge about the effects of reduced Gsk-3 activity could be important in the context of these diseases.</p><p>In this paper, we describe the analysis of genome-wide gene expression patterns in <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>ESCs. Since the loss of Gsk-3 activity results in the activation of numerous signaling pathways simultaneously, we further dissected the effects of losing Gsk-3 activity by examining gene expression patterns in ESCs with either constitutively active PI3K-mediated insulin signaling or constitutively active Wnt signaling.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2-1"><title>Mouse embryonic stem cell culture</title><p>wild-type (WT) mouse ESCs (E14K), <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>(<xref rid="B23" ref-type="bibr">23</xref>), p110* (<xref rid="B9" ref-type="bibr">9</xref>), and &#x003b2;-catenin S33A (<xref rid="B39" ref-type="bibr">39</xref>) stable cell lines, along with respective control WT ESCs stably transfected with puromycin-resistant plasmids, were grown on 0.1% gelatin-coated plates in high glucose DMEM (Life Technologies) supplemented with 15% fetal bovine serum (Hyclone), 1% non-essential amino acids, 1% sodium pyruvate, 1% <sc>l</sc>-glutamine, 1% penicillin/streptomycin (Life Technologies), 55&#x02009;&#x003bc;M 2-mercaptomethanol, and 1000&#x02009;U/ml ESGRO (Millipore). Media was replenished every other day.</p></sec><sec id="S2-2"><title>RNA isolation, cDNA synthesis, and quantitative PCR</title><p>RNA was isolated from 5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> to 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> ESCs using the MirVana Total RNA Isolation Kit (Applied Biosystems) according to the manufacturer&#x02019;s instructions. Two micrograms of RNA were then used for cDNA synthesis using the high capacity cDNA reverse transcription kit (Applied Biosystems) following the manufacturer&#x02019;s protocol. Quantitative RT-PCR was performed on an Applied Biosystems StepOne machine using TaqMan master mix and one of the following TaqMan assays (Applied Biosystems): Axin2 (Mm00443610_m1), Brachyury (Mm00436877_m1), Bhmt1 (Mm04210521_g1), Bhmt2 (Mm00517726_m1), Cdx2 (Mm01212280_m1), Ido2 (Mm00524206_m1), Anxa8 (Mm00507926_m1), Aqp8 (Mm0043 1846_m1), Gata6 (Mm00802636_m1), Wnt6 (Mm00437351_m1), Acta2 (Mm01546133_m1), or Foxq1 (Mm01157333_s1). Three biological replicates and three technical replicates were used for each cell type. All threshold cycle (Ct) values were normalized to a mouse Gapdh endogenous control (Mm99999915_g1) (Applied Biosystems), and relative quantification was calculated from the median Ct value (<xref rid="B40" ref-type="bibr">40</xref>). <italic>P</italic>-values were calculated using Data Assist software (Applied Biosystems).</p></sec><sec id="S2-3"><title>Microarray analysis</title><p>RNA was isolated using the MirVana Total RNA Isolation Kit (Applied Biosystems) according to the manufacturer&#x02019;s instructions. The concentration of RNA was measured in a Nanodrop ND-1000 UV-Vis spectrophotometer (Nanodrop) and an Agilent 2100 Bioanalyzer Lab-On-A-Chip Agilent 6000 Series II chip (Agilent) was used to determine the integrity of the samples. RNA from each cell line was hybridized onto a SurePrint G3 Mouse GE 8&#x02009;&#x000d7;&#x02009;60&#x02009;K Microarray, 8&#x02009;&#x000d7;&#x02009;60&#x02009;K, AMADID 028005 (Agilent). Hybridization was performed overnight at 45&#x000b0;C. We performed arrays for each cell line using RNA that was isolated in biological triplicate (<italic>n</italic>&#x02009;=&#x02009;3). For Gsk-3 DKO ESCs, we used <italic>n</italic>&#x02009;=&#x02009;4 biological replicates. SurePrint arrays were scanned with an Agilent G2505C Microarray Scanner (Agilent). The information about each probe on the arrays was extracted from the image data using Agilent Feature Extraction 10.9 (FE) and .txt files were generated. The raw intensity values from these files in imported into the mathematical software package &#x0201c;R,&#x0201d; which was used for all data input, diagnostic plots, normalization, and quality checking steps of the analysis process using scripts developed by Dr. Peter White, Director of the Biomedical Genomics Core at Nationwide Children&#x02019;s Hospital specifically for this analysis. These scripts call on several Bioconductor packages, an open-source and open-development software project to provide tools for the analysis and comprehension of genomic data (<xref rid="B41" ref-type="bibr">41</xref>). The algorithm used for normalization of gene expression was designed for use with Agilent One-Color Analysis. The median green (Cy3) intensities are normalized between the arrays using the Quantile Normalization package in &#x0201c;R&#x0201d; (<xref rid="B42" ref-type="bibr">42</xref>). Quantile normalization is a non-linear probe-level normalization that results in the same empirical distribution of intensities for each array. This is a significantly more robust approach than simply normalizing to the median value of each array. The genes that were altered by twofold either way and had a false discovery rate (FDR) of &#x0003c;10% were sorted and used for further interpretation of the microarray data.</p></sec><sec id="S2-4"><title>Statistical analysis of microarray data</title><p>Statistical analyses were performed using two well-validated and commonly used approaches &#x02013; significance analysis of microarrays (SAM) and adjusted <italic>p</italic>-value. SAM is a powerful tool for analyzing microarray gene expression data useful for identifying differentially expressed genes between two conditions (<xref rid="B43" ref-type="bibr">43</xref>). SAM calculates a test statistic for relative difference in gene 5 expression based on permutation analysis of expression data and calculates a FDR using the <italic>q</italic>-value method presented in Ref. (<xref rid="B44" ref-type="bibr">44</xref>). In outline, SAM identifies statistically significant genes by carrying out gene specific <italic>t</italic>-tests and computes a statistic for each gene, which measures the strength of the relationship between gene expression and a response variable. This analysis uses non-parametric statistics, since the data may not follow a normal distribution. The response variable describes and groups the data based on experimental conditions. In this method, repeated permutations of the data are used to determine if the expression of any gene is significant related to the response. The use of permutation-based analysis accounts for correlations in genes and avoids parametric assumptions about the distribution of individual genes. For this experiment, SAM analysis was implemented in R using the Bioconductor Siggenes package. In a one-color experimental design, a <italic>two-class unpaired</italic> analysis is typically performed for each experimental comparison, whereas in a two-color approach a <italic>one-class</italic> analysis is used. Typically, an FDR cutoff in the range of 10&#x02013;20% is chosen to maximize sensitivity without significantly impacting accuracy. For the current study, a 10% FDR was used to generate the list of significantly differentially expressed genes.</p><sec id="S2-4-1"><title>Adjusted <italic>p</italic>-value</title><p>The moderated <italic>t</italic>-statistic (<italic>t</italic>) is computer for each probe and for each contrast in the experimental design. This has the same interpretation as an ordinary <italic>t</italic>-statistic except that the standard errors have been moderated across genes, i.e., shrunk toward a common value. This has the effect of borrowing information from the ensemble of genes to aid with inference about each individual gene. The <italic>p</italic>-value is obtained from the distribution of the moderated <italic>t</italic>-statistic. Finally these <italic>p</italic>-values are adjusted for multiple testing using the Benjamini and Hochberg&#x02019;s (<xref rid="B45" ref-type="bibr">45</xref>) step-up method for controlling the FDR. This is the most popular method for <italic>p</italic>-value adjustment. If all genes with <italic>p</italic>-value below a threshold, say 0.05, are selected as differentially expressed, then the expected proportion of false discoveries in the selected group is controlled to be less than the threshold value, in this case 5%. For the current study, the adjusted <italic>p</italic>-values were calculated using the Bioconductor limma package.</p></sec></sec><sec id="S2-5"><title>Gene enrichment analysis</title><p>After filtering gene lists to remove duplicates, the HGNC symbols for genes increased or decreased by twofold or more were entered into ToppFun, within the ToppGene Suite (toppgene.cchmc.org) (<xref rid="B46" ref-type="bibr">46</xref>). ToppGene then performs functional enrichments, looking for sets of co-regulated genes. Calculations are performed using FDR for correction, and a <italic>p</italic>-value cutoff of &#x0003c;0.05.</p></sec></sec><sec id="S3"><title>Results</title><p>We had previously analyzed the genome-wide expression in <italic>Gsk-3</italic>&#x003b1;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>; <italic>Gsk-3</italic>&#x003b2;<sup>&#x02212;</sup><italic><sup>/</sup></italic><sup>&#x02212;</sup>ESCs (hereafter referred to as <italic>Gsk-3</italic> double knockout; <italic>Gsk-3</italic> DKO) using Affymetrix microarrays, and found hundreds of genes whose expression was significantly increased or decreased compared to WT ESCs (<xref rid="B9" ref-type="bibr">9</xref>). Here, we repeated this microarray analysis using the Agilent platform. For all of the microarray gene expression analyses, we used a twofold or greater change in gene expression as our threshold for significance. We also isolated RNA and performed the hybridization to the microarrays at the same time to reduce experiment-to-experiment variability. Consistent with our previous results using the Affymetrix platform, we found 1313 genes up-regulated twofold or more in <italic>Gsk-3</italic> DKO ESCs, while 2178 genes were down-regulated twofold or more (a complete list of genes can be found in Datasheet <xref ref-type="supplementary-material" rid="SM1">1</xref> in Supplementary Material). One of the important signaling pathways regulated by Gsk-3 is the Wnt pathway (<xref rid="B47" ref-type="bibr">47</xref>). We therefore expected our microarray data from <italic>Gsk-3</italic> DKO ESCs to reveal many of the same Wnt target genes that have been demonstrated experimentally in a variety of model systems [Wnt Homepage, <uri xlink:type="simple" xlink:href="http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes">www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes</uri>]. A few well-established direct targets of Wnt signaling, such as <italic>Brachyury</italic> (<italic>T</italic>) and <italic>Axin2</italic>, were found to be increased substantially in <italic>Gsk-3</italic> DKO ESCs (162.5- and 8.6-fold, respectively) (Table <xref ref-type="table" rid="T1">1</xref>). We were surprised, however, to find that <italic>Brachyury</italic> and <italic>Axin2</italic> were the exception of the 65 Wnt putative target genes; we identified in our microarray data from <italic>Gsk-3</italic> DKO ESCs that only seven additional genes (<italic>Sp5, Cdx1, Stra6, Lef1, Cyclin D1, PTTG</italic>, and <italic>Fgf18</italic>) had their expression increased more than twofold (Table <xref ref-type="table" rid="T1">1</xref>). In fact, 13 Wnt target genes showed decreased expression of more than twofold (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Comparison of known Wnt target genes to their expression levels in Gsk-3 DKO and S33A ESCs as determined by microarray</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1">DKO</th><th align="center" rowspan="1" colspan="1">S33A</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Brachyury</td><td align="center" style="color:red" rowspan="1" colspan="1">162.5</td><td align="center" style="color:red" rowspan="1" colspan="1">41.7</td></tr><tr><td align="left" rowspan="1" colspan="1">SP5</td><td align="center" style="color:red" rowspan="1" colspan="1">75.8</td><td align="center" style="color:red" rowspan="1" colspan="1">15.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Cdx1</td><td align="center" style="color:red" rowspan="1" colspan="1">16.5</td><td align="center" style="color:red" rowspan="1" colspan="1">82.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Axin-2</td><td align="center" style="color:red" rowspan="1" colspan="1">8.6</td><td align="center" style="color:red" rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Stra6</td><td align="center" style="color:red" rowspan="1" colspan="1">4.8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">LEF1</td><td align="center" style="color:red" rowspan="1" colspan="1">4</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;7&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclin D</td><td align="center" style="color:red" rowspan="1" colspan="1">3.1</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Pituitary tumor transforming gene (PTTG)</td><td align="center" style="color:red" rowspan="1" colspan="1">2.2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">FGF18</td><td align="center" style="color:red" rowspan="1" colspan="1">2.1</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.9</td></tr><tr><td align="left" rowspan="1" colspan="1">BMP4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR&#x003b4;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Endothelin-1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Telomerase</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">LGR5/GPR49</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Jagged</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">sFRP-2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">CD44</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">c-myc binding protein</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Msl1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitric oxide synthase 2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Nkx2.2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">c-myc</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Met</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Claudin-1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Id2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">FoxN1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Gbx2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP-7</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Osteoprotegerin</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Wnt3a</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurogenin 1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Tiam1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">FGF20</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Cdx4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.1</td><td align="center" style="color:red" rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Sox17</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Oct-4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Runx2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Sox2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Frizzled 7</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.3</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02009;&#x02009;&#x02212;2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastrin</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Sox9</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">CCN1/Cyr61</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Follistatin</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">NeuroD1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.5</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02009;&#x02009;&#x02212;5.6</td></tr><tr><td align="left" rowspan="1" colspan="1">c-jun</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.6</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02009;&#x02009;&#x02212;2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Nr-CAM</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">SALL4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.6</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02009;&#x02009;&#x02212;2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanog</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">FGF9</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.7</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Irx3 and Six3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Cacna1&#x003b3;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP2, MMP9</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.9</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">LBH</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2&#x02009;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Pitx2</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212; 1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">ITF-2</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.3</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212; 1.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Twist</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Periostin</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.4</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">VEGF</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" style="color:red" rowspan="1" colspan="1">&#x02009;&#x02009;2.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Snail</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;2.8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212; 1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Tcf-1 (Hnf1a)</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3&#x02009;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212; 1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">n-myc</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Gremlin</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">EGF receptor</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;3.8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212; 1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Delta-like 1</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;4.3</td></tr><tr><td align="left" rowspan="1" colspan="1">WISP</td><td align="center" style="color:green" rowspan="1" colspan="1">&#x02212;10&#x02009;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212; 1.1</td></tr></tbody></table><table-wrap-foot><p><italic>The list of genes was found at The Wnt Homepage website (<uri xlink:type="simple" xlink:href="http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes">www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes</uri>). Genes whose expression increased more than twofold are shown in red, while genes whose expression decreased more than twofold are shown in green</italic>.</p></table-wrap-foot></table-wrap><p>The relative paucity of up-regulated Wnt target genes was surprising, especially, since it has been shown that a reporter construct containing multimerized Lef/Tcf binding sites is strongly activated in <italic>Gsk-3</italic> DKO ESCs [(<xref rid="B23" ref-type="bibr">23</xref>); unpublished observation]. Therefore, we wanted to compare the gene expression data from <italic>Gsk-3</italic> DKO ESCs with another mouse embryonic stem cell line that has constitutively active Wnt signaling. WT ESCs stably expressing a form of &#x003b2;-catenin in which serine 33 has been mutated to an alanine (S33A) that prevents the phosphorylation by Gsk-3 on this residue as well as subsequent ubiquitination, resulting in the constitutive activation of Wnt signaling. These cells have previously been shown to potently activate the expression of several Wnt target genes (<xref rid="B39" ref-type="bibr">39</xref>). The &#x003b2;-catenin S33A cells and their control cells were included in our microarray experiment to investigate how similar the patterns of gene expression were compared to <italic>Gsk-3</italic> DKO ESCs.</p><p>Microarray data showed that 1468 genes were up-regulated twofold or more in S33A cells compared to control cells, while 1412 genes were down-regulated twofold or more. As expected, we confirmed the high levels of <italic>Brachyury, Axin2</italic>, and <italic>Cdx1</italic> that were also observed in the <italic>Gsk-3</italic> DKO ESCs; however, only three additional genes (<italic>Sp5, Cdx4</italic>, and <italic>VEGF</italic>) showed a twofold or greater increase in gene expression in the S33A ESCs (Table <xref ref-type="table" rid="T1">1</xref>). And similar to the data from <italic>Gsk-3</italic> DKO ESCs, 12 Wnt target genes are down-regulated twofold or more in S33A cells (Table <xref ref-type="table" rid="T1">1</xref>). Taken together, these data show that some Wnt target genes, such as <italic>Brachyury</italic> and <italic>Axin2</italic>, are indeed transcribed at high levels in two different cell lines in which Wnt signaling is constitutively active &#x02013; <italic>Gsk-3</italic> DKO and &#x003b2;-catenin S33A. Our data also show that many Wnt target genes are not activated in these cell lines as was predicted.</p><p>Initially, we had expected that many of the genes whose expression was significantly increased in <italic>Gsk-3</italic> DKO ESCs would be due to activation of the Wnt pathway. Since we did not observe the increased expression of Wnt target genes, we asked whether the activation of another Gsk-3-dependent signaling pathway could explain the data. Because the genetic deletion of Gsk-3 isoforms likely leads to the activation of signaling pathways other than the Wnt pathway, we speculated that the combined effect of multiple pathway activation likely leads to new patterns of gene expression. Another important signal transduction pathway that is regulated by Gsk-3 activity is the insulin signaling pathway. To investigate the contribution of insulin signaling to the effects on gene expression seen in the <italic>Gsk-3</italic> DKO ESCs, we analyzed genome-wide microarray gene expression data from WT ESCs stably expressing a constitutively active form of the p110 subunit of PI3K (p110*) (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Eight hundred sixty-four genes were up-regulated twofold or more in p110* ESCs compared to control cells, while 1660 genes were down-regulated twofold or more.</p><p>After compiling the list of genes whose expression was significantly changed in <italic>Gsk-3</italic> DKO, p110*, and S33A ESCs, we were curious as to the similarities and disparities in the patterns of gene expression in these cell lines. To perform this evaluation, we removed all duplicate probes from our lists of genes from the microarray experiment, and we then sorted based on changes seen in each list. The <italic>Gsk-3</italic> DKO and p110* ESCs had 1313 and 864 genes, respectively, that were up-regulated twofold or more. Of these, 206 genes were up-regulated in both cell types (Figure <xref ref-type="fig" rid="F1">1</xref>A). Similarly, 1468 genes were up-regulated by at least twofold in S33A cells, and 336 of these genes overlapped with the 1313 genes up-regulated in the <italic>Gsk-3</italic> DKO ESCs (Figure <xref ref-type="fig" rid="F1">1</xref>A). As we expected, there was relatively little overlap in the genes up-regulated in both p110* and S33A ESCs; only 119 genes were in common between these gene sets (Figure <xref ref-type="fig" rid="F1">1</xref>A). This comparison of up-regulated genes shows a greater degree of overlap between <italic>Gsk-3</italic> DKO and S33A ESCs than with <italic>Gsk-3</italic> DKO and p110* ESCs.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Venn diagram representing the overlap in genes whose expression is changed at least twofold in <italic>Gsk-3</italic> DKO, p110*, and &#x003b2;-catenin S33A ESCs</bold>. <bold>(A)</bold> Representation of genes whose expression was increased in <italic>Gsk-3</italic> DKO (blue; 1313 genes total), p110* (red; 864 genes total), and S33A ESCs (green; 1468 genes total). Genes whose expression is increased in multiple genes sets are denoted by the numbers at the interface of the gene sets. <bold>(B)</bold> Representation of genes whose expression was decreased in <italic>Gsk-3</italic> DKO (blue; 2178 genes total), p110* (red; 1660 genes total), and S33A ESCs (green; 1412 genes total). Genes whose expression is decreased in multiple genes sets are denoted by the numbers at the interface of the gene sets.</p></caption><graphic xlink:href="fendo-05-00133-g001"/></fig><p>Interestingly, the similarities between gene sets were even greater when examining the genes whose expression was down-regulated twofold or more. Two thousand one hundred seventy-eight genes showed decreased expression in <italic>Gsk-3</italic> DKO ESCs, compared with 1660 genes in p110* ESCs and 1412 genes in S33A ESCs. Furthermore, we found that 987 genes were in common between p110* and <italic>Gsk-3</italic> DKO ESCs, while only 516 genes were shared between S33A and <italic>Gsk-3</italic> DKO ESCs (Figure <xref ref-type="fig" rid="F1">1</xref>B). This pattern is striking in that it is the opposite of what was seen with the up-regulated genes, with a greater overlap between <italic>Gsk-3</italic> DKO and p110* ESCs. In addition, the overlap between p110* and S33A ESCs was also more pronounced, with the same 289 genes down-regulated at least twofold in both cell lines (Figure <xref ref-type="fig" rid="F1">1</xref>B). These data suggest that the loss of <italic>Gsk-3</italic> in ESCs results in the up-regulation of mostly distinct genes in either p110* or S33A ESCs, but that those genes that are down-regulated in the absence of <italic>Gsk-3</italic> share a greater overlap in cells with activated PI3K signaling and activated Wnt signaling.</p><p>Since different sets of genes were either increased or decreased in expression in p110* and S33A ESCs, we bioinformatically performed enrichment analyses to see if functionally related genes were co-regulated in a signaling pathway-specific fashion (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>). Genes that were up-regulated in <italic>Gsk-3</italic> DKO ESCs were involved in gene ontology (GO): molecular function of protein domain (GO:0019904) and also the GO: biological process for cilium organization (GO:0044782). In addition, genes encoding for CD molecules, tumor necrosis factor receptor superfamily, and intraflagellar transport homologs were up-regulated. Genes that were increased in expression in p110* ESCs showed an enrichment for the GO: molecular function of piRNA binding (GO:0034584) and an showed an increase in expression in genes encoding for zinc fingers, C2H2, and BTB domain-containing (ZBTB). In addition, both <italic>Gsk-3</italic> DKO and p110* ESCs showed increased expression of genes involved in urothelium and lower urinary tract development. For genes up-regulated in S33A ESCs, the top GO: molecular function clusters were genes involved in organic acid binding (GO:0043177) and protein homodimerization activity (GO:0042803). Also, a significant number of genes that contain homeobox domains were up-regulated in the S33A ESCs, as well as a high number of genes encoding for CD molecules.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Summary of enrichment analysis of genes up-regulated in Gsk-3 DKO, p110*, and S33A ESCs</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">ID</th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" rowspan="1" colspan="1">Hit count</th></tr></thead><tbody><tr><td align="left" colspan="4" style="background-color:DarkGray;" rowspan="1"><bold>GSK-3 DKO ESCs</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GO: molecular function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Protein domain specific binding</td><td align="center" rowspan="1" colspan="1">GO:0019904</td><td align="center" rowspan="1" colspan="1">1.01&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">55/633</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: biological process</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Cilium organization</td><td align="center" rowspan="1" colspan="1">GO:0044782</td><td align="center" rowspan="1" colspan="1">6.06&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td><td align="center" rowspan="1" colspan="1">19/123</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Gene family</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">CD molecules</td><td align="center" rowspan="1" colspan="1">CD</td><td align="center" rowspan="1" colspan="1">5.14&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8</sup></td><td align="center" rowspan="1" colspan="1">21/276</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor necrosis factor receptor superfamily</td><td align="center" rowspan="1" colspan="1">TNFRSF</td><td align="center" rowspan="1" colspan="1">5.77&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">4/12</td></tr><tr><td align="left" rowspan="1" colspan="1">Intraflagellar transport homologs</td><td align="center" rowspan="1" colspan="1">IFT</td><td align="center" rowspan="1" colspan="1">1.52&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;4</sup></td><td align="center" rowspan="1" colspan="1">4/15</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Coexpression Atlas</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Mendel_RNAseq_e17.5_urothelium</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.74&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;16</sup></td><td align="center" rowspan="1" colspan="1">101/989</td></tr><tr><td align="left" rowspan="1" colspan="1">Developing lower urinary tract_e13.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.04&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup></td><td align="center" rowspan="1" colspan="1">82/802</td></tr><tr><td align="left" colspan="4" style="background-color:DarkGray;" rowspan="1"><bold>P110*</bold><bold>ESCs</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: molecular function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">piRNA binding</td><td align="center" rowspan="1" colspan="1">GO:0034584</td><td align="center" rowspan="1" colspan="1">3.17&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">3/3</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Gene family</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Zinc fingers, C2H2, and BTB domain containing</td><td align="center" rowspan="1" colspan="1">ZBTB</td><td align="center" rowspan="1" colspan="1">5.33&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">6/47</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Coexpression Atlas</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Mendel_RNAseq_e17.5_urothelium</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.58&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup></td><td align="center" rowspan="1" colspan="1">65/989</td></tr><tr><td align="left" rowspan="1" colspan="1">Developing lower urinary tract_e13.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.30&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td><td align="center" rowspan="1" colspan="1">30/802</td></tr><tr><td align="left" colspan="4" style="background-color:DarkGray;" rowspan="1"><bold>S33A ESCs</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: molecular function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Organic acid binding</td><td align="center" rowspan="1" colspan="1">GO:0043177</td><td align="center" rowspan="1" colspan="1">4.93&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">26/230</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein homodimerization activity</td><td align="center" rowspan="1" colspan="1">GO:0042803</td><td align="center" rowspan="1" colspan="1">5.15&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">56/674</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Gene family</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">CD molecules</td><td align="center" rowspan="1" colspan="1">CD</td><td align="center" rowspan="1" colspan="1">5.08&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td><td align="center" rowspan="1" colspan="1">18/276</td></tr></tbody></table><table-wrap-foot><p><italic>Bonferroni correction method</italic>.</p><p><italic>All <italic>p</italic>-Value cutoffs &#x02013; 0.05</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><bold>Summary of enrichment analysis of genes down-regulated in Gsk-3 DKO, p110*, and S33A ESCs</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">ID</th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" rowspan="1" colspan="1">Hit count</th></tr></thead><tbody><tr><td align="left" colspan="4" style="background-color:DarkGray;" rowspan="1"><bold>GSK-3 DKO ESCs</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: molecular function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Sequence-specific DNA binding</td><td align="center" rowspan="1" colspan="1">GO:0043565</td><td align="center" rowspan="1" colspan="1">8.59&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup></td><td align="center" rowspan="1" colspan="1">109/726</td></tr><tr><td align="left" rowspan="1" colspan="1">Sequence-specific DNA binding transcription factor activity</td><td align="center" rowspan="1" colspan="1">GO:0003700</td><td align="center" rowspan="1" colspan="1">7.28&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;12</sup></td><td align="center" rowspan="1" colspan="1">141/1067</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: biological process</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular system development</td><td align="center" rowspan="1" colspan="1">GO:00722358</td><td align="center" rowspan="1" colspan="1">2.15&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;21</sup></td><td align="center" rowspan="1" colspan="1">148/871</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pathway</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Extracellular matrix organization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.40&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;9</sup></td><td align="center" rowspan="1" colspan="1">50/264</td></tr><tr><td align="left" rowspan="1" colspan="1">Elastic fiber formation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.51&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;7</sup></td><td align="center" rowspan="1" colspan="1">15/41</td></tr><tr><td align="left" colspan="4" style="background-color:DarkGray;" rowspan="1"><bold>P110</bold>* <bold>ESCs</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: molecular function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Receptor binding</td><td align="center" rowspan="1" colspan="1">GO:0005102</td><td align="center" rowspan="1" colspan="1">1.51&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;11</sup></td><td align="center" rowspan="1" colspan="1">133/1341</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: biological process</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Organ morphogenesis</td><td align="center" rowspan="1" colspan="1">GO:0009887</td><td align="center" rowspan="1" colspan="1">2.09&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;34</sup></td><td align="center" rowspan="1" colspan="1">147/876</td></tr><tr><td align="left" rowspan="1" colspan="1">Extracellular matrix organization</td><td align="center" rowspan="1" colspan="1">GO:0030198</td><td align="center" rowspan="1" colspan="1">1.59&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;22</sup></td><td align="center" rowspan="1" colspan="1">70/330</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular system development</td><td align="center" rowspan="1" colspan="1">GO:0072358</td><td align="center" rowspan="1" colspan="1">2.34&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;22</sup></td><td align="center" rowspan="1" colspan="1">124/871</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pathway</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Extracellular matrix organization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.17&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;16</sup></td><td align="center" rowspan="1" colspan="1">54/264</td></tr><tr><td align="left" colspan="4" style="background-color:DarkGray;" rowspan="1"><bold>S33A ESCs</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: molecular function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Sequence-specific DNA binding</td><td align="center" rowspan="1" colspan="1">GO:0043565</td><td align="center" rowspan="1" colspan="1">2.15&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup></td><td align="center" rowspan="1" colspan="1">81/726</td></tr><tr><td align="left" rowspan="1" colspan="1">Sequence-specific DNA binding transcription factor activity</td><td align="center" rowspan="1" colspan="1">GO:0003700</td><td align="center" rowspan="1" colspan="1">3.54&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup></td><td align="center" rowspan="1" colspan="1">105/1067</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>GO: biological process</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Neurogenesis</td><td align="center" rowspan="1" colspan="1">GO:0022008</td><td align="center" rowspan="1" colspan="1">3.88&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;15</sup></td><td align="center" rowspan="1" colspan="1">143/1360</td></tr><tr><td align="left" rowspan="1" colspan="1">Extracellular matrix organization</td><td align="center" rowspan="1" colspan="1">GO:0072358</td><td align="center" rowspan="1" colspan="1">1.21&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;14</sup></td><td align="center" rowspan="1" colspan="1">104/871</td></tr></tbody></table><table-wrap-foot><p><italic>Bonferroni correction method</italic>.</p><p><italic>All <italic>p</italic>-Value cutoffs &#x02013; 0.05</italic>.</p></table-wrap-foot></table-wrap><p>We found it notable that the enrichments among down-regulated genes were more robust than among the up-regulated genes (Table <xref ref-type="table" rid="T4">4</xref>). For genes decreased twofold or more in <italic>Gsk-3</italic> DKO ESCs, the greatest enrichment for GO: molecular function was in genes encoding for sequence-specific DNA binding, i.e., transcription factors (GO:0043565). In addition, a large number of genes involved in the development of the cardiovascular system (GO:0072358) were down-regulated in <italic>Gsk-3</italic> DKO ESCs. Also decreased in expression were genes involved in extracellular matrix organization and elastic fiber formation. For down-regulated genes in p110* ESCs, the most enriched GO: molecular function was for genes involved in receptor binding (GO:0005102), while the highest enrichment for GO: biological processes were for organ morphogenesis (GO: 0009887), extracellular matrix organization (GO:0030198), and cardiovascular system development (GO:0072358). Furthermore, many genes involved in extracellular matrix organization were decreased in p110* ESCs. Genes down-regulated in S33A ESCs were enriched for genes encoding sequence-specific DNA binding (GO:0043565), as well as enrichment for genes involved in neurogenesis (GO:0022008) and cardiovascular system development (GO:0072358). The results from these enrichment analyses showed several similarities and differences with respect to the genes that have increased or decreased expression in <italic>Gsk-3</italic> DKO, p110*, and S33A ESCs, and provide a framework for beginning to better understand the complex interrelationships between PI3K-mediated signaling and Wnt signaling, as well as providing important insights into the patterns of gene expression seen in <italic>Gsk-3</italic> DKO ESCs.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p><bold>Summary of comparison between microarray and qPCR gene expression data in Gsk-3 DKO, S33A, and p110* ESCs for genes described in this work</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">DKO<hr/></th><th align="center" colspan="2" rowspan="1">S33A<hr/></th><th align="center" colspan="2" rowspan="1">p110*<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Microarray</th><th align="center" rowspan="1" colspan="1">qPCR</th><th align="center" rowspan="1" colspan="1">Microarray</th><th align="center" rowspan="1" colspan="1">qPCR</th><th align="center" rowspan="1" colspan="1">Microarray</th><th align="center" rowspan="1" colspan="1">qPCR</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Axin2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">6.7&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">7.0&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">3.6&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">3.7&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.7&#x000d7;</td><td align="right" rowspan="1" colspan="1">&#x02212;2.5&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Brachyury</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">162.5&#x000d7;</td><td align="center" rowspan="1" colspan="1">622&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">41.7&#x000d7;</td><td align="center" rowspan="1" colspan="1">38&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.5&#x000d7;</td><td align="right" rowspan="1" colspan="1">&#x02212;1.4&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Bhmt2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">5.7&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">13.1&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">60.8&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">56.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;2.6&#x000d7;</td><td align="right" rowspan="1" colspan="1">1.3&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cd&#x000d7;2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">27.6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">5.3&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">33.3&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">12.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2&#x000d7;</td><td align="center" rowspan="1" colspan="1">1&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Bhmt1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">6.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">14.1&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">49.1&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">70.1&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;5.5&#x000d7;</td><td align="right" rowspan="1" colspan="1">2.8&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ido2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">9.4&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">81.4&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">3.4&#x000d7;</td><td align="center" rowspan="1" colspan="1">20&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.3&#x000d7;</td><td align="right" rowspan="1" colspan="1">1.4&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Wnt6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">2.3&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.2&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">10.1&#x000d7;</td><td align="right" rowspan="1" colspan="1">5.7&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">An&#x000d7;a8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.7&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.4&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">6.8&#x000d7;</td><td align="right" rowspan="1" colspan="1">3.6&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Gata6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.1&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;3.1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;2.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;31.8&#x000d7;</td><td align="right" rowspan="1" colspan="1">3.4&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Aqp8</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.6&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;2.6</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;3.3&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;48.9&#x000d7;</td><td align="right" rowspan="1" colspan="1">1.7&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fo&#x000d7;q1</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.4&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.1&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;2.9&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">1.5&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;31.5&#x000d7;</td><td align="right" rowspan="1" colspan="1">&#x02212;1.7&#x000d7;</td></tr><tr><td align="left" rowspan="1" colspan="1">Acta2</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;400.3&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;5.0&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;1.8&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">2.3&#x000d7;</td><td align="char" char="." charoff="50" rowspan="1" colspan="1">&#x02212;165.6&#x000d7;</td><td align="right" rowspan="1" colspan="1">&#x02212;2.5&#x000d7;</td></tr></tbody></table><table-wrap-foot><p><italic>Decreases in gene expression are denoted by negative values</italic>.</p></table-wrap-foot></table-wrap><p>While the data obtained from microarray experiments can provide an excellent overall view of differential patterns of gene expression, it is nonetheless very important to use an independent technique to experimentally validate the changes in gene expression that were observed via microarray. Therefore, we selected a handful of genes whose expression patterns we of interest, and we performed quantitative reverse-transcriptase PCR (qPCR) using TaqMan probes on RNA isolated from <italic>Gsk-3</italic> DKO, p110*, S33A ESCs, and their respective control cell lines. As an initial quality control measure, we performed qPCR to validate the expression of the known Wnt target genes, <italic>Axin2</italic> and <italic>Brachyury</italic>. As expected, we saw substantial increases in gene expression in both <italic>Gsk-3</italic> DKO and S33A ESCs for <italic>Axin2</italic> (up 7-fold in <italic>Gsk-3</italic> DKO and 3.7-fold in S33A ESCs) and <italic>Brachyury</italic> (up 622-fold in <italic>Gsk-3</italic> DKO and 38-fold in S33A ESCs), while both genes has reduced expression in p110* ESCs (0.4- and 0.7-fold changes, respectively) (Figure <xref ref-type="fig" rid="F2">2</xref>). These results are consistent with <italic>Axin2</italic> and <italic>Brachyury</italic> being Wnt target genes.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Validation of the expression of the Wnt target genes, <italic>Axin2</italic> and <italic>Brachyury</italic> in <italic>Gsk-3</italic> DKO ESCs, &#x003b2;-catenin S33A ESCs, and p110* ESCs</bold>. <bold>(A)</bold> Quantitative PCR of <italic>Axin2</italic> showing the expression, relative to WT control. <bold>(B)</bold> Quantitative PCR of <italic>Brachyury</italic> showing the expression, relative to WT control. For both results: RQ&#x02009;=&#x02009;relative quantification (all values were normalized to a <italic>Gapdh</italic> endogenous control). Error bars represent standard error of the mean (SEM) between biological replicates (<italic>n</italic>&#x02009;=&#x02009;3) and technical replicates (<italic>n</italic>&#x02009;=&#x02009;3; <italic>n</italic>&#x02009;=&#x02009;9 total for each gene in each cell line) (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, two-tailed <italic>t</italic>-test). Fold changes compared to WT are shown.</p></caption><graphic xlink:href="fendo-05-00133-g002"/></fig><p>We then proceeded to validating the expression of additional genes whose expression levels were shown to be substantially increased or reduced in the microarray experiments. We selected four genes, <italic>Bhmt1</italic> (<italic>Betaine-homocysteine methyltransferase</italic>), <italic>Bhmt2</italic> (<italic>Betaine-homocysteine methyltransferase</italic> 2), <italic>Cdx2</italic> (<italic>Caudal-type homeobox 2</italic>), and <italic>Ido2</italic> (<italic>Indoleamine 2,3-dioxygenase 2</italic>), whose expression, by microarray, was shown to be up-regulated in both <italic>Gsk-3</italic> DKO and S33A ESCs, but not p110* ESCs. Validation by qPCR showed that the expression of <italic>Bhmt1</italic> was up 14.1- and 70.1-fold in <italic>Gsk-3</italic> DKO and S33A ESCs, respectively, compared to a modest 2.8-fold increase in p110* ESCs (Figure <xref ref-type="fig" rid="F3">3</xref>). Similarly <italic>Bhmt2</italic> expression was shown to be increased 13.1-fold in <italic>Gsk-3</italic> DKO ESCs and 56.5-fold in S33A ESCs, while expression was only increased by 1.3-fold in p110* ESCs (Figure <xref ref-type="fig" rid="F3">3</xref>). The expression of <italic>Cdx2</italic> was increased 5.3- and 12.5-fold in <italic>Gsk-3</italic> DKO ESCs and S33A ESCs, respectively, but remained unchanged in p110* ESCs (Figure <xref ref-type="fig" rid="F3">3</xref>). Finally, qPCR showed that <italic>Ido2</italic> expression was increased 81.4-fold in <italic>Gsk-3</italic> DKO ESCs and 20-fold in S33A ESCs, while showing a minimal 1.4-fold increase in expression in p110* ESCs (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Validation of genes whose expression is increased in <italic>Gsk-3</italic> DKO and &#x003b2;-catenin S33A ESCs, but not p110* ESCs</bold>. <bold>(A)</bold> qPCR of <italic>Bhmt2</italic> showing the expression, relative to WT control. <bold>(B)</bold> qPCR of <italic>Cdx2</italic> showing the expression, relative to WT control. <bold>(C)</bold> qPCR of <italic>Bhmt1</italic> showing the expression, relative to WT control. <bold>(D)</bold> qPCR of <italic>Ido2</italic> showing the expression, relative to WT control. For all results shown: RQ&#x02009;=&#x02009;relative quantification (all values were normalized to a <italic>Gapdh</italic> endogenous control); error bars represent standard error of the mean (SEM) between biological replicates (<italic>n</italic>&#x02009;=&#x02009;3) and technical replicates (<italic>n</italic>&#x02009;=&#x02009;3; <italic>n</italic>&#x02009;=&#x02009;9 total for each gene in each cell line) (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, two-tailed <italic>t</italic>-test); and fold changes compared to WT are shown.</p></caption><graphic xlink:href="fendo-05-00133-g003"/></fig><p>Next, we chose to perform similar qPCR validation on genes whose expression was changed in <italic>Gsk-3</italic> DKO and p110* ESCs, but not in S33A ESCs. We selected six genes for analysis &#x02013; <italic>Wnt6, Anxa8 (Annexin 8), Gata6 (GATA binding protein 6), Aqp8 (Aquaporin 8), Foxq1 (Forkhead box Q1)</italic>, and <italic>Acta2 (actin</italic>, &#x003b1;<italic>2, smooth muscle, aorta)</italic>. All of the genes that we assayed showed lower changes in gene expression compared to that seen by microarray. For example, microarray data showed that <italic>Wnt6</italic> and <italic>Anxa8</italic> were up-regulated in p110* ESCs 10.1- and 6.8-fold, respectively; however, qPCR revealed that the expression of <italic>Wnt6</italic> and <italic>Anxa8</italic> was about half of that &#x02013; 5.7- and 3.6-fold, respectively (Figure <xref ref-type="fig" rid="F4">4</xref>). Similarly, while <italic>Gata6, Aqp8, Foxq1</italic>, and <italic>Acta2</italic> all showed at least 30-fold reductions in gene expression in p110* ESCs by microarray, the qPCR results revealed more subtle changes, ranging from a 3.4-fold increase for <italic>Gata6</italic> to a 2.5-fold reduction in <italic>Acta2</italic> (Table <xref ref-type="table" rid="T3">3</xref>). Importantly, the expression of these genes in S33A ESCs was quite different. For example, while <italic>Gata6</italic> expression was up 3.4-fold in p110* ESCs, <italic>Gata6</italic> expression was decreased 2.5-fold in S33A ESCs (Figure <xref ref-type="fig" rid="F5">5</xref>). Similarly, <italic>Acta2</italic> expression was decreased 2.5-fold in p110* ESCs, while <italic>Acta2</italic> expression was increased 2.3-fold in S33A ESCs (Figure <xref ref-type="fig" rid="F5">5</xref>). These results are consistent with opposing effects of PI3K-mediated insulin signaling and Wnt signaling having distinct effects on gene expression.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Validation of genes whose expression is increased in p110* ESCs, but not S33A ESCs</bold>. <bold>(A)</bold> qPCR of <italic>Wnt6</italic>. <bold>(B)</bold> qPCR of <italic>Anxa8</italic>. <bold>(C)</bold> qPCR of <italic>Wnt6</italic>. <bold>(D)</bold> qPCR of <italic>Anxa8</italic>. For all results shown: RQ&#x02009;=&#x02009;relative quantification (all values were normalized to a <italic>Gapdh</italic> endogenous control); error bars represent standard error of the mean (SEM) between biological replicates (<italic>n</italic>&#x02009;=&#x02009;3) and technical replicates (<italic>n</italic>&#x02009;=&#x02009;3; <italic>n</italic>&#x02009;=&#x02009;9 total for each gene in each cell line) (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, two-tailed <italic>t</italic> test); and fold changes compared to WT are shown.</p></caption><graphic xlink:href="fendo-05-00133-g004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Validation of genes whose expression is decreased in p110* ESCs, but not S33A ESCs</bold>. <bold>(A)</bold> qPCR of <italic>Foxq1</italic>. <bold>(B)</bold> qPCR of <italic>Acta2</italic>. For both results: RQ&#x02009;=&#x02009;relative quantification (all values were normalized to a <italic>Gapdh</italic> endogenous control); error bars represent standard error of the mean (SEM) between biological replicates (<italic>n</italic>&#x02009;=&#x02009;3) and technical replicates (<italic>n</italic>&#x02009;=&#x02009;3; <italic>n</italic>&#x02009;=&#x02009;9 total for each gene in each cell line) (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, two-tailed <italic>t</italic> test); and fold changes compared to WT are shown.</p></caption><graphic xlink:href="fendo-05-00133-g005"/></fig></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>The analysis of gene expression changes in <italic>Gsk-3</italic> DKO ESCs revealed almost 3500 genes whose expression increased or decreased at least twofold, reinforcing the notion that Gsk-3 activity broadly regulates the expression of many genes. Our data, which examined global changes in gene expression in several clonal cell lines, illuminated numerous interesting and unexpected features of Gsk-3-dependent signal transduction.</p><p>We had initially expected to find many known Wnt target genes to be up-regulated in a Gsk-3 and &#x003b2;-catenin-dependent fashion and this was indeed true for <italic>Axin2</italic> (<xref rid="B48" ref-type="bibr">48</xref>) and <italic>Brachyury</italic>. However, most of the other Wnt target genes did not show significant increases in expression, and in fact, almost twice as many genes showed decreases in expression. It is possible that this simply reflects differences in the regulation of gene expression between cell types; alternatively, this data could provide a readout of affected genes due to the constitutive activation of Wnt signaling arising from the genetic deletion of <italic>Gsk-3</italic>&#x003b1; and <italic>Gsk-3</italic>&#x003b2;. Furthermore, since these ESCs have been deficient in <italic>Gsk-3</italic>&#x003b1; and <italic>Gsk-3</italic>&#x003b2; since their successful homologous recombination event, it is possible that downstream negative feedback effects serve to modify the expression of Wnt target genes, making the changes in gene expression not appear as dramatic as expected.</p><p>We do, however, identify several putative novel Wnt target genes, whose expression is increased in both <italic>Gsk-3</italic> DKO and &#x003b2;-catenin S33A ESCs. <italic>Cdx2, Ido2, Bhmt1</italic>, and <italic>Bhmt2</italic> were all confirmed by qPCR to conform to the microarray expression profiling. Interestingly, the transcription factor <italic>Cdx2</italic>, was recently shown to be a direct target of Wnt signaling in the mouse, independently confirming our observation (<xref rid="B49" ref-type="bibr">49</xref>). Furthermore, while <italic>Ido1</italic> has been shown to be a Wnt target gene (<xref rid="B50" ref-type="bibr">50</xref>), <italic>Ido2</italic> has not. In the mouse genome, the <italic>Ido1</italic> and <italic>Ido2</italic> genes lie next to each other on chromosome 8 (8qA2) and are transcribed in the same direction. Thus, one possibility is that &#x003b2;-catenin-mediated transcription could influence both genes from the <italic>Ido1</italic> promoter. Alternatively, there may be additional Lef/Tcf binding sites in the <italic>Ido2</italic> promoter. An <italic>in silico</italic> search (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>) for Lef/Tcf binding sites in the mouse <italic>Ido2</italic> promoter identified eight putative binding sites within 2&#x02009;kb of the transcription start site (TSS). Further detailed studies will be required to verify whether any of these putative binding sites are bona fide Lef/Tcf binding sites.</p><p>Similarly, Bhmt1 and Bhmt2 are also contiguous in the mouse genome (13qC3). Neither gene had previously been shown to be regulated by Wnt signaling, but we find both genes have increased expression in <italic>Gsk-3</italic> DKO ESCs (14.1- and 13.1-fold, respectively) and even more potently expressed in &#x003b2;-catenin S33A ESCs (up 70.1- and 56.5-fold, respectively). <italic>Bhmt1</italic> and <italic>Bhmt2</italic> both encode for betaine&#x02013;homocysteine <italic>S</italic>-methyltransferase enzymes, participating in the regulation of homocysteine levels (<xref rid="B53" ref-type="bibr">53</xref>). Interestingly, variations in <italic>BHMT1</italic> and <italic>BHMT2</italic> have also been implicated in the development of cleft palate in certain human populations (<xref rid="B54" ref-type="bibr">54</xref>&#x02013;<xref rid="B56" ref-type="bibr">56</xref>). Interestingly, mice deficient in <italic>Gsk-3</italic>&#x003b2; develop cleft palate (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). It is unclear whether this phenotype is a consequence of altered expression of <italic>Bhmt1</italic> or <italic>Bhmt2</italic>, but based on the data presented here, there may be a functional connection between these observations.</p><p>While not as dramatic as the changes seen for putative Wnt target genes, we found several genes whose expression was insensitive to constitutively active Wnt signaling, but were increased or decreased in expression in a Gsk-3/PI3K-dependent manner. It has been demonstrated in animal models of various cancers that the transcription factor ZEB1 activates PI3K signaling (<xref rid="B57" ref-type="bibr">57</xref>&#x02013;<xref rid="B59" ref-type="bibr">59</xref>) and this results in increased expression of <italic>Gata6</italic> (<xref rid="B60" ref-type="bibr">60</xref>). Our data from mouse ESCs stably expressing a constitutively active form of the p110 subunit of PI3K corroborates these findings and show that the PI3K-mediated increase in <italic>Gata6</italic> expression is not limited to cancer cell populations. <italic>Wnt6, Anxa8</italic>, and <italic>Aqp8</italic> also showed increased expression in p110* ESCs, while all but <italic>Anxa8</italic> had reduced expression in S33A ESCs. While PI3K signaling has been shown to regulate the subcellular localization of <italic>Aqp8</italic> in hepatocytes (<xref rid="B61" ref-type="bibr">61</xref>), this is the first report that activation of PI3K signaling has an effect on <italic>Aqp8</italic> transcription. <italic>Anxa8</italic> expression has been shown to be down-regulated by epidermal growth factor (EGF)-stimulated PI3K signaling in a model of metastatic cholangiocarcinoma (<xref rid="B62" ref-type="bibr">62</xref>), while we find that <italic>Anxa8</italic> expression is increased 3.6-fold in p110* ESCs, likely reflecting cell-type differences in <italic>Anxa8</italic> gene regulation. It should be mentioned that we selected <italic>Gata6, Wnt6, Anxa8</italic>, and <italic>Aqp8</italic> for validation by qPCR because these genes showed increased expression in both <italic>Gsk-3</italic> DKO and p110* ESCs by microarray; however, the qPCR results showed only modest changes in gene expression in the <italic>Gsk-3</italic> DKO ESCs, highlighting the importance of not relying on microarray gene expression data alone.</p><p>Finally, we also found that the expression of <italic>Foxq1</italic> and <italic>Acta2</italic> were decreased in p110* ESCs. <italic>Acta2</italic> showed the most robust changes in expression (down fivefold in <italic>Gsk-3</italic> DKO ESCs, down 2.5-fold in p110* ESCs, and up 2.3-fold in S33A ESCs). We did find that <italic>Foxq1</italic> expression is modestly decreased in p110* ESCs and increased 1.5-fold in S33A ESCs. <italic>Foxq1</italic> has recently been shown to be one of the most highly expressed genes in human colorectal cancer and has been shown to be a direct target of Wnt signaling, which is often constitutively activated in colorectal cancer cells (<xref rid="B63" ref-type="bibr">63</xref>). Based on these data, we expected to find increased <italic>Foxq1</italic> expression in both <italic>Gsk-3</italic> DKO and S33A ESCs, but we did not observe these expected increases. It will be interesting to determine the mechanism responsible for the lack of response by <italic>Foxq1</italic> to constitutively activated Wnt signaling in the context of mouse ESCs.</p><p>Taken together, our data shows that, while many genes have their expression changed in <italic>Gsk-3</italic> DKO ESCs, only a fraction of the changes we observe are due to activated Wnt signaling or activated PI3K signaling, meaning that there are likely several other signaling pathways whose activation affects <italic>Gsk-3</italic>-dependent gene expression. Thus, our data provide a framework for future analyses to make these connections. Furthermore, while these studies were performed in mouse ESCs, we believe that the findings from this study can be used in future studies examining the role of insulin or Wnt signaling pathways in other biological settings, such as the study of insulin resistance in the diabetic brain.</p></sec><sec id="S5"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="supplementary-material" id="S6"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at <uri xlink:type="simple" xlink:href="http://www.frontiersin.org/Journal/10.3389/fendo.2014.00133/abstract">http://www.frontiersin.org/Journal/10.3389/fendo.2014.00133/abstract</uri></p><supplementary-material content-type="local-data" id="SM1"><label>Datasheet 1</label><caption><p><bold>Microarray gene expression data for Gsk-3 DKO ESCs, &#x003b2;-catenin S33A ESCs and p110* ESCs</bold>. Tabs at the bottom of the spreadsheet contain the microarray data, either as All Data, or sorted by fold changes in expression as seen in Gsk-3 DKO, p110*, or &#x003b2;-catenin S33A ESCs. Within each tab is found the Agilent probe ID, Gene symbol, Gene name, NCBI accession number, Entrez Gene ID, fold-changes (FC) compared to WT ESCs, false-discovery rates (FDR) compared to WT ESCs, and adjusted P-values (AdjP) compared to WT ESCs. The normalized microarray values for each individual sample, as well as the averages, are also shown.</p></caption><media xlink:href="Data_Sheet1.XLSX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>This work was supported by NIH R01AG031883 and funds from the University of Colorado Denver.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Embi</surname><given-names>N</given-names></name><name><surname>Rylatt</surname><given-names>DB</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group>
<article-title>Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase</article-title>. <source>Eur J Biochem</source> (<year>1980</year>) <volume>107</volume>:<fpage>519</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1980.tb06059.x</pub-id><pub-id pub-id-type="pmid">6249596</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group>
<article-title>Molecular cloning and expression of glycogen synthase kinase-3/factor A</article-title>. <source>EMBO J</source> (<year>1990</year>) <volume>9</volume>:<fpage>2431</fpage>&#x02013;<lpage>8</lpage><?supplied-pmid 2164470?><pub-id pub-id-type="pmid">2164470</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buescher</surname><given-names>JL</given-names></name><name><surname>Phiel</surname><given-names>CJ</given-names></name></person-group>
<article-title>A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity</article-title>. <source>J Biol Chem</source> (<year>2010</year>) <volume>285</volume>:<fpage>7957</fpage>&#x02013;<lpage>63</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.091603</pub-id><?supplied-pmid 20080974?><pub-id pub-id-type="pmid">20080974</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>CA</given-names></name><name><surname>Jope</surname><given-names>RS</given-names></name></person-group>
<article-title>The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling</article-title>. <source>Prog Neurobiol</source> (<year>2001</year>) <volume>65</volume>:<fpage>391</fpage>&#x02013;<lpage>426</lpage><pub-id pub-id-type="doi">10.1016/S0301-0082(01)00024-7</pub-id><?supplied-pmid 11527574?><pub-id pub-id-type="pmid">11527574</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frame</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group>
<article-title>GSK3 takes centre stage more than 20 years after its discovery</article-title>. <source>Biochem J</source> (<year>2001</year>) <volume>359</volume>:<fpage>1</fpage>&#x02013;<lpage>16</lpage><pub-id pub-id-type="doi">10.1042/0264-6021:3590001</pub-id><?supplied-pmid 11563964?><pub-id pub-id-type="pmid">11563964</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group>
<article-title>GSK-3: tricks of the trade for a multi-tasking kinase</article-title>. <source>J Cell Sci</source> (<year>2003</year>) <volume>116</volume>:<fpage>1175</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1242/jcs.00384</pub-id><?supplied-pmid 12615961?><pub-id pub-id-type="pmid">12615961</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>D</given-names></name><name><surname>Alessi</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Andjelkovich</surname><given-names>M</given-names></name><name><surname>Hemmings</surname><given-names>B</given-names></name></person-group>
<article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title>. <source>Nature</source> (<year>1995</year>) <volume>378</volume>:<fpage>785</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/378785a0</pub-id><?supplied-pmid 8524413?><pub-id pub-id-type="pmid">8524413</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klippel</surname><given-names>A</given-names></name><name><surname>Reinhard</surname><given-names>C</given-names></name><name><surname>Kavanaugh</surname><given-names>WM</given-names></name><name><surname>Apell</surname><given-names>G</given-names></name><name><surname>Escobedo</surname><given-names>MA</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group>
<article-title>Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways</article-title>. <source>Mol Cell Biol</source> (<year>1996</year>) <volume>16</volume>: <fpage>4117</fpage>&#x02013;<lpage>27</lpage><?supplied-pmid 8754810?><pub-id pub-id-type="pmid">8754810</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popkie</surname><given-names>AP</given-names></name><name><surname>Zeidner</surname><given-names>LC</given-names></name><name><surname>Albrecht</surname><given-names>AM</given-names></name><name><surname>D&#x02019;Ippolito</surname><given-names>A</given-names></name><name><surname>Eckardt</surname><given-names>S</given-names></name><name><surname>Newsom</surname><given-names>DE</given-names></name><etal/></person-group>
<article-title>Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci</article-title>. <source>J Biol Chem</source> (<year>2010</year>) <volume>285</volume>:<fpage>41337</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.170704</pub-id><?supplied-pmid 21047779?><pub-id pub-id-type="pmid">21047779</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Mitsui</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group>
<article-title>Role of ERas in promoting tumour-like properties in mouse embryonic stem cells</article-title>. <source>Nature</source> (<year>2003</year>) <volume>423</volume>:<fpage>541</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1038/nature01646</pub-id><?supplied-pmid 12774123?><pub-id pub-id-type="pmid">12774123</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group>
<article-title>Wnt/beta-catenin signaling and disease</article-title>. <source>Cell</source> (<year>2012</year>) <volume>149</volume>:<fpage>1192</fpage>&#x02013;<lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id><pub-id pub-id-type="pmid">22682243</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinfeld</surname><given-names>B</given-names></name><name><surname>Albert</surname><given-names>I</given-names></name><name><surname>Porfiri</surname><given-names>E</given-names></name><name><surname>Fiol</surname><given-names>C</given-names></name><name><surname>Munemitsu</surname><given-names>S</given-names></name><name><surname>Polakis</surname><given-names>P</given-names></name></person-group>
<article-title>Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly</article-title>. <source>Science</source> (<year>1996</year>) <volume>272</volume>:<fpage>1023</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.272.5264.1023</pub-id><?supplied-pmid 8638126?><pub-id pub-id-type="pmid">8638126</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yost</surname><given-names>C</given-names></name><name><surname>Torres</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Kimelman</surname><given-names>D</given-names></name><name><surname>Moon</surname><given-names>R</given-names></name></person-group>
<article-title>The axis-inducing activity, stability, and subcellular distribution of b-catenin is regulated in <italic>Xenopus</italic> embryos by glycogen synthase kinase 3</article-title>. <source>Genes Dev</source> (<year>1996</year>) <volume>10</volume>:<fpage>1443</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1101/gad.10.12.1443</pub-id><?supplied-pmid 8666229?><pub-id pub-id-type="pmid">8666229</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>H</given-names></name><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Stappert</surname><given-names>J</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Kemler</surname><given-names>R</given-names></name></person-group>
<article-title>beta-catenin is a target for the ubiquitin-proteasome pathway</article-title>. <source>EMBO J</source> (<year>1997</year>) <volume>16</volume>:<fpage>3797</fpage>&#x02013;<lpage>804</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.13.3797</pub-id><?supplied-pmid 9233789?><pub-id pub-id-type="pmid">9233789</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Doble</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Habas</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>mechanism for Wnt co-receptor phosphorylation and activation</article-title>. <source>Nature</source> (<year>2005</year>) <volume>438</volume>:<fpage>873</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature04185</pub-id><?supplied-pmid 16341017?><pub-id pub-id-type="pmid">16341017</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Garcia Abreu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group>
<article-title>Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6</article-title>. <source>PLoS One</source> (<year>2009</year>) <volume>4</volume>:<fpage>e4926</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0004926</pub-id><?supplied-pmid 19293931?><pub-id pub-id-type="pmid">19293931</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taelman</surname><given-names>VF</given-names></name><name><surname>Dobrowolski</surname><given-names>R</given-names></name><name><surname>Plouhinec</surname><given-names>JL</given-names></name><name><surname>Fuentealba</surname><given-names>LC</given-names></name><name><surname>Vorwald</surname><given-names>PP</given-names></name><name><surname>Gumper</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes</article-title>. <source>Cell</source> (<year>2010</year>) <volume>143</volume>:<fpage>1136</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.11.034</pub-id><?supplied-pmid 21183076?><pub-id pub-id-type="pmid">21183076</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korinek</surname><given-names>V</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>van Wichen</surname><given-names>D</given-names></name><name><surname>de Weger</surname><given-names>R</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><etal/></person-group>
<article-title>Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma</article-title>. <source>Science</source> (<year>1997</year>) <volume>275</volume>:<fpage>1784</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1126/science.275.5307.1784</pub-id><?supplied-pmid 9065401?><pub-id pub-id-type="pmid">9065401</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Korinek</surname><given-names>V</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC</article-title>. <source>Science</source> (<year>1997</year>) <volume>275</volume>:<fpage>1787</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1126/science.275.5307.1787</pub-id><?supplied-pmid 9065402?><pub-id pub-id-type="pmid">9065402</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Rubie</surname><given-names>EA</given-names></name><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Jin</surname><given-names>O</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group>
<article-title>Requirement for glycogen synthase kinase-3beta in cell survival and NF- kappaB activation [see comments]</article-title>. <source>Nature</source> (<year>2000</year>) <volume>406</volume>:<fpage>86</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1038/35017574</pub-id><?supplied-pmid 10894547?><pub-id pub-id-type="pmid">10894547</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>KJ</given-names></name><name><surname>Arron</surname><given-names>JR</given-names></name><name><surname>Stankunas</surname><given-names>K</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name><name><surname>Longaker</surname><given-names>MT</given-names></name></person-group>
<article-title>Chemical rescue of cleft palate and midline defects in conditional GSK-3beta mice</article-title>. <source>Nature</source> (<year>2007</year>) <volume>446</volume>:<fpage>79</fpage>&#x02013;<lpage>82</lpage><pub-id pub-id-type="doi">10.1038/nature05557</pub-id><?supplied-pmid 17293880?><pub-id pub-id-type="pmid">17293880</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacAulay</surname><given-names>K</given-names></name><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Hansotia</surname><given-names>T</given-names></name><name><surname>Sinclair</surname><given-names>EM</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism</article-title>. <source>Cell Metab</source> (<year>2007</year>) <volume>6</volume>:<fpage>329</fpage>&#x02013;<lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.08.013</pub-id><?supplied-pmid 17908561?><pub-id pub-id-type="pmid">17908561</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>GA</given-names></name><name><surname>Kockeritz</surname><given-names>LK</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group>
<article-title>Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines</article-title>. <source>Dev Cell</source> (<year>2007</year>) <volume>12</volume>:<fpage>957</fpage>&#x02013;<lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2007.04.001</pub-id><?supplied-pmid 17543867?><pub-id pub-id-type="pmid">17543867</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F</given-names></name><name><surname>Popkie</surname><given-names>AP</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Phiel</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>Gsk3beta is required in the epithelium for palatal elevation in mice</article-title>. <source>Dev Dyn</source> (<year>2010</year>) <volume>239</volume>:<fpage>3235</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1002/dvdy.22466</pub-id><?supplied-pmid 20981831?><pub-id pub-id-type="pmid">20981831</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrell</surname><given-names>WB</given-names></name><name><surname>Szabo-Rogers</surname><given-names>HL</given-names></name><name><surname>Liu</surname><given-names>KJ</given-names></name></person-group>
<article-title>Novel reporter alleles of GSK-3alpha and GSK-3beta</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e50422</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0050422</pub-id><?supplied-pmid 23185619?><pub-id pub-id-type="pmid">23185619</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WY</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>GSK-3 is a master regulator of neural progenitor homeostasis</article-title>. <source>Nat Neurosci</source> (<year>2009</year>) <volume>12</volume>:<fpage>1390</fpage>&#x02013;<lpage>97</lpage><pub-id pub-id-type="doi">10.1038/nn.2408</pub-id><?supplied-pmid 19801986?><pub-id pub-id-type="pmid">19801986</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>VW</given-names></name><name><surname>Chen</surname><given-names>RH</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group>
<article-title>Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling</article-title>. <source>J Biol Chem</source> (<year>2000</year>) <volume>275</volume>:<fpage>32475</fpage>&#x02013;<lpage>81</lpage><pub-id pub-id-type="doi">10.1074/jbc.M005342200</pub-id><?supplied-pmid 10913153?><pub-id pub-id-type="pmid">10913153</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McManus</surname><given-names>EJ</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Armit</surname><given-names>LJ</given-names></name><name><surname>Ronaldson</surname><given-names>L</given-names></name><name><surname>Shpiro</surname><given-names>N</given-names></name><name><surname>Marquez</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis</article-title>. <source>EMBO J</source> (<year>2005</year>) <volume>24</volume>:<fpage>1571</fpage>&#x02013;<lpage>83</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600633</pub-id><?supplied-pmid 15791206?><pub-id pub-id-type="pmid">15791206</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Mahmoudi</surname><given-names>T</given-names></name><name><surname>Danenberg</surname><given-names>E</given-names></name><name><surname>Bejaoui</surname><given-names>I</given-names></name><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Korswagen</surname><given-names>HC</given-names></name><etal/></person-group>
<article-title>Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade</article-title>. <source>J Biol Chem</source> (<year>2009</year>) <volume>284</volume>:<fpage>35308</fpage>&#x02013;<lpage>13</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.078261</pub-id><?supplied-pmid 19850932?><pub-id pub-id-type="pmid">19850932</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>PS</given-names></name><name><surname>Melton</surname><given-names>DA</given-names></name></person-group>
<article-title>A molecular mechanism for the effect of lithium on development</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1996</year>) <volume>93</volume>:<fpage>8455</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.16.8455</pub-id><?supplied-pmid 8710892?><pub-id pub-id-type="pmid">8710892</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Ruel</surname><given-names>L</given-names></name><name><surname>Woodgett</surname><given-names>J</given-names></name></person-group>
<article-title>Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells</article-title>. <source>Curr Biol</source> (<year>1996</year>) <volume>6</volume>:<fpage>1664</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(02)70790-2</pub-id><?supplied-pmid 8994831?><pub-id pub-id-type="pmid">8994831</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phiel</surname><given-names>CJ</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name></person-group>
<article-title>Molecular Targets of Lithium Action</article-title>. <source>Annu Rev Pharmacol Toxicol</source> (<year>2001</year>) <volume>41</volume>:<fpage>789</fpage>&#x02013;<lpage>813</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.789</pub-id><?supplied-pmid 11264477?><pub-id pub-id-type="pmid">11264477</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryder</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>B</given-names></name></person-group>
<article-title>Divergent roles of GSK3 and CDK5 in APP processing</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2003</year>) <volume>312</volume>:<fpage>922</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2003.11.014</pub-id><?supplied-pmid 14651959?><pub-id pub-id-type="pmid">14651959</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Ryder</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Fox</surname><given-names>N</given-names></name><name><surname>Solenberg</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing</article-title>. <source>Biochemistry</source> (<year>2004</year>) <volume>43</volume>:<fpage>6899</fpage>&#x02013;<lpage>908</lpage><pub-id pub-id-type="doi">10.1021/bi035627j</pub-id><?supplied-pmid 15170327?><pub-id pub-id-type="pmid">15170327</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phiel</surname><given-names>CJ</given-names></name><name><surname>Wilson</surname><given-names>CA</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name></person-group>
<article-title>GSK-3a regulates production of Alzheimer&#x02019;s disease amyloid-b peptides</article-title>. <source>Nature</source> (<year>2003</year>) <volume>423</volume>:<fpage>435</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature01640</pub-id><pub-id pub-id-type="pmid">12761548</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>W</given-names></name><name><surname>Planel</surname><given-names>E</given-names></name><name><surname>Zehr</surname><given-names>C</given-names></name><name><surname>Olm</surname><given-names>V</given-names></name><name><surname>Meyerson</surname><given-names>J</given-names></name><name><surname>Suleman</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2005</year>) <volume>102</volume>:<fpage>6990</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.0500466102</pub-id><?supplied-pmid 15867159?><pub-id pub-id-type="pmid">15867159</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sereno</surname><given-names>L</given-names></name><name><surname>Coma</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Sanchez-Ferrer</surname><given-names>P</given-names></name><name><surname>Sanchez</surname><given-names>MB</given-names></name><name><surname>Gich</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>A novel GSK-3beta inhibitor reduces Alzheimer&#x02019;s pathology and rescues neuronal loss in vivo</article-title>. <source>Neurobiol Dis</source> (<year>2009</year>) <volume>35</volume>:<fpage>359</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.05.025</pub-id><?supplied-pmid 19523516?><pub-id pub-id-type="pmid">19523516</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurtado</surname><given-names>DE</given-names></name><name><surname>Molina-Porcel</surname><given-names>L</given-names></name><name><surname>Carroll</surname><given-names>JC</given-names></name><name><surname>Macdonald</surname><given-names>C</given-names></name><name><surname>Aboagye</surname><given-names>AK</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group>
<article-title>Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer&#x02019;s disease</article-title>. <source>J Neurosci</source> (<year>2012</year>) <volume>32</volume>:<fpage>7392</fpage>&#x02013;<lpage>402</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0889-12.2012</pub-id><?supplied-pmid 22623685?><pub-id pub-id-type="pmid">22623685</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>KF</given-names></name><name><surname>Ng</surname><given-names>DY</given-names></name><name><surname>Jayakumaran</surname><given-names>G</given-names></name><name><surname>Wood</surname><given-names>GA</given-names></name><name><surname>Koide</surname><given-names>H</given-names></name><name><surname>Doble</surname><given-names>BW</given-names></name></person-group>
<article-title>beta-catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism</article-title>. <source>Cell Stem Cell</source> (<year>2011</year>) <volume>8</volume>:<fpage>214</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.12.010</pub-id><?supplied-pmid 21295277?><pub-id pub-id-type="pmid">21295277</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmittgen</surname><given-names>TD</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name></person-group>
<article-title>Analyzing real-time PCR data by the comparative C(T) method</article-title>. <source>Nat Protoc</source> (<year>2008</year>) <volume>3</volume>:<fpage>1101</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id><?supplied-pmid 18546601?><pub-id pub-id-type="pmid">18546601</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>RC</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Bates</surname><given-names>DM</given-names></name><name><surname>Bolstad</surname><given-names>B</given-names></name><name><surname>Dettling</surname><given-names>M</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title>. <source>Genome Biol</source> (<year>2004</year>) <volume>5</volume>:<fpage>R80</fpage><pub-id pub-id-type="doi">10.1186/gb-2004-5-10-r80</pub-id><?supplied-pmid 15461798?><pub-id pub-id-type="pmid">15461798</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Astrand</surname><given-names>M</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group>
<article-title>A comparison of normalization methods for high density oligonucleotide array data based on variance and bias</article-title>. <source>Bioinformatics</source> (<year>2003</year>) <volume>19</volume>:<fpage>185</fpage>&#x02013;<lpage>93</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/19.2.185</pub-id><?supplied-pmid 12538238?><pub-id pub-id-type="pmid">12538238</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tusher</surname><given-names>VG</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>G</given-names></name></person-group>
<article-title>Significance analysis of microarrays applied to the ionizing radiation response</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2001</year>) <volume>98</volume>:<fpage>5116</fpage>&#x02013;<lpage>21</lpage><pub-id pub-id-type="doi">10.1073/pnas.091062498</pub-id><?supplied-pmid 11309499?><pub-id pub-id-type="pmid">11309499</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>JD</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group>
<article-title>Statistical significance for genomewide studies</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2003</year>) <volume>100</volume>:<fpage>9440</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.1530509100</pub-id><?supplied-pmid 12883005?><pub-id pub-id-type="pmid">12883005</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>
<article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat Soc B</source> (<year>1995</year>) <volume>57</volume>:<fpage>289</fpage>&#x02013;<lpage>300</lpage></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Bardes</surname><given-names>EE</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Jegga</surname><given-names>AG</given-names></name></person-group>
<article-title>ToppGene Suite for gene list enrichment analysis and candidate gene prioritization</article-title>. <source>Nucleic Acids Res</source> (<year>2009</year>) <volume>37</volume>:<fpage>W305</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp427</pub-id><?supplied-pmid 19465376?><pub-id pub-id-type="pmid">19465376</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>BT</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group>
<article-title>Wnt/beta-catenin signaling: components, mechanisms, and diseases</article-title>. <source>Dev Cell</source> (<year>2009</year>) <volume>17</volume>:<fpage>9</fpage>&#x02013;<lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id><?supplied-pmid 19619488?><pub-id pub-id-type="pmid">19619488</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jho</surname><given-names>EH</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Domon</surname><given-names>C</given-names></name><name><surname>Joo</surname><given-names>CK</given-names></name><name><surname>Freund</surname><given-names>JN</given-names></name><name><surname>Costantini</surname><given-names>F</given-names></name></person-group>
<article-title>Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway</article-title>. <source>Mol Cell Biol</source> (<year>2002</year>) <volume>22</volume>:<fpage>1172</fpage>&#x02013;<lpage>83</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.4.1172-1183.2002</pub-id><?supplied-pmid 11809808?><pub-id pub-id-type="pmid">11809808</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Gan</surname><given-names>Q</given-names></name><name><surname>Stokes</surname><given-names>A</given-names></name><name><surname>Lassiter</surname><given-names>RN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>beta-catenin regulates Pax3 and Cdx2 for caudal neural tube closure and elongation</article-title>. <source>Development</source> (<year>2014</year>) <volume>141</volume>:<fpage>148</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="doi">10.1242/dev.101550</pub-id><?supplied-pmid 24284205?><pub-id pub-id-type="pmid">24284205</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soichot</surname><given-names>M</given-names></name><name><surname>Hennart</surname><given-names>B</given-names></name><name><surname>Al Saabi</surname><given-names>A</given-names></name><name><surname>Leloire</surname><given-names>A</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Levy-Marchal</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>:<fpage>e25470</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0025470</pub-id><?supplied-pmid 21980470?><pub-id pub-id-type="pmid">21980470</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messeguer</surname><given-names>X</given-names></name><name><surname>Escudero</surname><given-names>R</given-names></name><name><surname>Farre</surname><given-names>D</given-names></name><name><surname>Nunez</surname><given-names>O</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Alba</surname><given-names>MM</given-names></name></person-group>
<article-title>PROMO: detection of known transcription regulatory elements using species-tailored searches</article-title>. <source>Bioinformatics</source> (<year>2002</year>) <volume>18</volume>:<fpage>333</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/18.2.333</pub-id><?supplied-pmid 11847087?><pub-id pub-id-type="pmid">11847087</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farre</surname><given-names>D</given-names></name><name><surname>Roset</surname><given-names>R</given-names></name><name><surname>Huerta</surname><given-names>M</given-names></name><name><surname>Adsuara</surname><given-names>JE</given-names></name><name><surname>Rosello</surname><given-names>L</given-names></name><name><surname>Alba</surname><given-names>MM</given-names></name><etal/></person-group>
<article-title>Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN</article-title>. <source>Nucleic Acids Res</source> (<year>2003</year>) <volume>31</volume>:<fpage>3651</fpage>&#x02013;<lpage>3</lpage><pub-id pub-id-type="doi">10.1093/nar/gkg605</pub-id><?supplied-pmid 12824386?><pub-id pub-id-type="pmid">12824386</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajares</surname><given-names>MA</given-names></name><name><surname>Perez-Sala</surname><given-names>D</given-names></name></person-group>
<article-title>Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism?</article-title>
<source>Cell Mol Life Sci</source> (<year>2006</year>) <volume>63</volume>:<fpage>2792</fpage>&#x02013;<lpage>803</lpage><pub-id pub-id-type="doi">10.1007/s00018-006-6249-6</pub-id><?supplied-pmid 17086380?><pub-id pub-id-type="pmid">17086380</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name></person-group>
<article-title>BHMT gene polymorphisms as risk factors for cleft lip and cleft palate in a Chinese population</article-title>. <source>Biomed Environ Sci</source> (<year>2011</year>) <volume>24</volume>:<fpage>89</fpage>&#x02013;<lpage>93</lpage><pub-id pub-id-type="doi">10.3967/0895-3988.2011.02.001</pub-id><?supplied-pmid 21565678?><pub-id pub-id-type="pmid">21565678</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinelli</surname><given-names>M</given-names></name><name><surname>Masiero</surname><given-names>E</given-names></name><name><surname>Carinci</surname><given-names>F</given-names></name><name><surname>Morselli</surname><given-names>PG</given-names></name><name><surname>Pezzetti</surname><given-names>F</given-names></name><name><surname>Scapoli</surname><given-names>L</given-names></name></person-group>
<article-title>New evidence for the role of cystathionine beta-synthase in non-syndromic cleft lip with or without cleft palate</article-title>. <source>Eur J Oral Sci</source> (<year>2011</year>) <volume>119</volume>:<fpage>193</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0722.2011.00824.x</pub-id><?supplied-pmid 21564312?><pub-id pub-id-type="pmid">21564312</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostowska</surname><given-names>A</given-names></name><name><surname>Hozyasz</surname><given-names>KK</given-names></name><name><surname>Biedziak</surname><given-names>B</given-names></name><name><surname>Misiak</surname><given-names>J</given-names></name><name><surname>Jagodzinski</surname><given-names>PP</given-names></name></person-group>
<article-title>Polymorphisms located in the region containing BHMT and BHMT2 genes as maternal protective factors for orofacial clefts</article-title>. <source>Eur J Oral Sci</source> (<year>2010</year>) <volume>118</volume>:<fpage>325</fpage>&#x02013;<lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0722.2010.00757.x</pub-id><?supplied-pmid 20662904?><pub-id pub-id-type="pmid">20662904</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ramjaun</surname><given-names>AR</given-names></name><name><surname>Haiko</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Warne</surname><given-names>PH</given-names></name><name><surname>Nicke</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice</article-title>. <source>Cell</source> (<year>2007</year>) <volume>129</volume>:<fpage>957</fpage>&#x02013;<lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.03.051</pub-id><?supplied-pmid 17540175?><pub-id pub-id-type="pmid">17540175</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Iwanaga</surname><given-names>K</given-names></name><name><surname>Raso</surname><given-names>MG</given-names></name><name><surname>Wislez</surname><given-names>M</given-names></name><name><surname>Hanna</surname><given-names>AE</given-names></name><name><surname>Wieder</surname><given-names>ED</given-names></name><etal/></person-group>
<article-title>Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer</article-title>. <source>PLoS One</source> (<year>2008</year>) <volume>3</volume>:<fpage>e2220</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0002220</pub-id><?supplied-pmid 18493606?><pub-id pub-id-type="pmid">18493606</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubrovska</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Salamone</surname><given-names>RJ</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Maira</surname><given-names>SM</given-names></name><name><surname>Garcia-Echeverria</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2009</year>) <volume>106</volume>:<fpage>268</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1073/pnas.0810956106</pub-id><?supplied-pmid 19116269?><pub-id pub-id-type="pmid">19116269</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ahn</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Gibbons</surname><given-names>DL</given-names></name><etal/></person-group>
<article-title>ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism</article-title>. <source>J Clin Invest</source> (<year>2014</year>) <volume>124</volume>:<fpage>2696</fpage>&#x02013;<lpage>708</lpage><pub-id pub-id-type="doi">10.1172/JCI72171</pub-id><?supplied-pmid 24762440?><pub-id pub-id-type="pmid">24762440</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradilone</surname><given-names>SA</given-names></name><name><surname>Carreras</surname><given-names>FI</given-names></name><name><surname>Lehmann</surname><given-names>GL</given-names></name><name><surname>Marinelli</surname><given-names>RA</given-names></name></person-group>
<article-title>Phosphoinositide 3-kinase is involved in the glucagon-induced translocation of aquaporin-8 to hepatocyte plasma membrane</article-title>. <source>Biol Cell</source> (<year>2005</year>) <volume>97</volume>:<fpage>831</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1042/BC20040115</pub-id><?supplied-pmid 15859947?><pub-id pub-id-type="pmid">15859947</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Yu</surname><given-names>GR</given-names></name><name><surname>Yoo</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Yoon</surname><given-names>BI</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><etal/></person-group>
<article-title>ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma</article-title>. <source>Gastroenterology</source> (<year>2009</year>) <volume>137</volume>:<fpage>1138</fpage>&#x02013;<lpage>50</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.04.015</pub-id><?supplied-pmid 19376120?><pub-id pub-id-type="pmid">19376120</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>J</given-names></name><name><surname>Bentz</surname><given-names>S</given-names></name><name><surname>Sengstag</surname><given-names>T</given-names></name><name><surname>Shastri</surname><given-names>VP</given-names></name><name><surname>Anderle</surname><given-names>P</given-names></name></person-group>
<article-title>FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e60051</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0060051</pub-id><?supplied-pmid 23555880?><pub-id pub-id-type="pmid">23555880</pub-id></mixed-citation></ref></ref-list></back></article>